The hypothesis of our study is that elacridar, a third-generation P-gp inhibitor, can effectively inhibit P-gp activity and reverse multidrug resistance in ovarian cancer cell lines, thereby enhancing sensitivity to chemotherapeutics in vitro. This evidence concerns the gene PGP and ovarian carcinoma.